SAN FRANCISCO, March 9, 2026, 06:57 PDT
Olema Pharmaceuticals (OLMA) tumbled over 40% in early Monday trading. Roche’s oral breast cancer drug, giredestrant, missed its primary endpoint in a pivotal first-line trial, and investors saw that as a warning sign for Olema’s own lead candidate, palazestrant. 1
This is significant—Olema belongs to a select cluster of biotechs backing oral drugs that inhibit or degrade the estrogen receptor, and Roche’s outcomes have served as a bellwether for the space before. After Roche unveiled upbeat Phase III data for giredestrant in November, Olema stock shot up over 220% premarket. 2
Roche reported that its phase III persevERA study testing giredestrant with palbociclib missed the mark on a statistically significant boost in progression-free survival compared to letrozole plus palbociclib among 992 first-line patients. Still, the company pointed to a numerical benefit and said the combo was well tolerated. 3
“While persevERA didn’t meet its main goal, we still see real promise for giredestrant as an endocrine therapy for early and advanced ER-positive breast cancer,” said Roche Chief Medical Officer Levi Garraway. Barclays’ James Gordon flagged that Roche shares might “overreact on sentiment.” Meanwhile, Jefferies’ Michael Leuchten said this miss should “completely reverse the positive momentum from late last year,” and pointed out that AstraZeneca’s trial design appeared stronger. 4
San Francisco’s Olema is pushing palazestrant through two Phase 3 trials. Back in November, the company reported that enrollment for OPERA-01—a monotherapy study targeting later-line metastatic breast cancer—continued on track. The headline readout is still slated for the back half of 2026. Olema closed out September holding $329 million in cash, cash equivalents and marketable securities. 5
Back in October, Olema CEO Sean Bohen pointed to “compelling progression-free survival and favorable tolerability” for palazestrant combined with ribociclib—data the company said justified pushing ahead with the OPERA-02 Phase 3 trial targeting first-line metastatic disease. But with shares sliding Monday, the market appears to be flagging that same trial as the weak link. 6
The field keeps getting more crowded. AstraZeneca last year said camizestrant slashed the risk of disease progression or death by 56% in a study guided by blood tests. Eli Lilly, for its part, picked up U.S. approval in September for Inluriyo, also known as imlunestrant, targeting ESR1-mutated advanced breast cancer, after late-stage data showed a 38% drop in risk of progression or death. 7
The comparison isn’t straightforward. On Monday, Investing.com cited Stifel analysts who said Roche’s data wasn’t great news for Olema right now, but noted that the numbers still give palazestrant a shot—thanks to its stronger antagonism and exposure profile. If that perspective pans out, the steep selloff on Monday might have gone too far. 8
The downside’s more straightforward. Roche missing may be a warning sign—first-line oral estrogen-receptor drugs could be running into resistance. That spells a potentially tougher market and valuation landscape for Olema’s OPERA-02, which is still a ways off. Investors, meanwhile, are waiting on the company’s more clear-cut catalyst: OPERA-01. Analysts see that readout coming in the second half of 2026. 9
